Universitéde Liége

Estetra Srl

Sanofi-Aventis

Estetra S.p.r.l.

Eyed Pharma

F. Hoffmann-La Roche Ag

Zimmermann Gerd

Hans-Willi Krell

Richard Endele

Pierre Bartsch

Jean-Michel Foidart

Didier Cataldo

Brigitte Evrard

Luc Delattre

Ekaterine Tskitishvili

Jean-Marie Rakic

Herman Jan Tijmen Coelingh Bennink

Gerd Zimmermann

Alain Badorc

Francoise Bono

Nathalie Guillo

Maud Jost

Marie-Francoise Bordes

Agnès Noel

Agnes Noel

Wout Wouters

Ludivine Petit

Renaud Viellevoye

Herman Jan Coelingh Bennink

The present invention relates to a combined oral contraceptive with a reduced risk for side effects, including a reduced risk for QT interval prolongation, a reduced risk for testosterone decrease and a reduced risk for elevated C-reactive protein levels when compared to other combined oral contraceptives. The estetrol/drospirenone combined oral contraceptive described herein shows favorable pharmacokinetics for the progestogenic component. Use of a specific estrogenic component in the combined oral contraceptive entails multiple benefits over currently available combined oral contraceptives.

Contraceptive compositions with reduced adverse effects

Described are methods of providing contraception in a woman having a BMI≥30.0 kg/m, comprising: selecting a woman determined to have a BMI≥30.0 kg/m, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg. Also described are methods of contraception that achieves a Pearl Index of <5 in women having a BMI≥30.0 kg/m, comprising: selecting a woman determined to have a BMI≥30.0 kg/m, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg, wherein the method comprises daily administration of the estetrol component and drospirenone on 24 consecutive days followed by a hormone-free period of 4 consecutive days.

Contraceptive methods with improved pearl index

The invention provides a sustained release intraocular drug delivery device comprising: (a) a polymeric matrix core into which at least one therapeutic agent is mixed, and; (b) a polymeric coating completely surrounding said polymeric matrix material; wherein said polymeric matrix core and polymeric coating are insoluble and inert in ocular fluids, and wherein said sustained release intraocular drug delivery device has a compliant annular segment shape and is to be inserted into the sulcus of the intact and/or pseudophakic eye.

Eye device

The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol in neurological disorders, such as diffuse white matter injury.

Estrogenic components for use in the treatment of neurological disorders

The present invention relates to a new use of tetrahydroxylated estrogens such as estetrol (1,3,5(10)-estratrien-3, 15&#x3b1;, 16&#x3b1;, 17&#x3b2;-tetrol), namely in a method of emergency contraception. The method of emergency contraception according to the invention comprises the oral administration of estetrol in a single dose within 120 hours of sexual intercourse.

Use of estetrol as emergency contraceptive

The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol, in neurological disorders, such as neonatal hypoxic-ischemic encephalopathy (HIE).

A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility.

Pharmaceutical compositions of pyrimidine-2,4,6-triones

The present invention thus relates to the use of 1,2,3-substituted indolizine derivatives in the preparation of medicaments of use in the treatment of diseases related to pathological choroidal angiogenesis, which derivatives correspond to the following general formula (I): 

Use of FGF inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis

The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.

Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases

Growing community of inventors

Trooz, Belgium

Jean-Michel Foidart